Kyriakos P Papadopoulos

25PUBLICATIONS
231CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Characterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Jul 23, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.

Masayuki Umeda, Ryan Hiltenbrand, Nicole L Michmerhuizen

|Jan 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.

Aung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian

|Oct 22, 2024
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.

Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni

|Oct 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson

|Jun 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Omid Hamid, Karl D Lewis, Amy Weise

Pageof 5

Frequent Collaborators

4 joint publications

Timothy A Yap

3 joint publications

Meredith McKean

3 joint publications

Melissa Lynne Johnson

3 joint publications

Aung Naing